Data Sheet (Cat.No.T10539)

TargetMol

BIBO3304 TFA

Chemical Properties



CAS No. : 191868-14-1

Formula: C31H36F3N7O5

Molecular Weight: 643.66

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BIBO3304 TFA is an effective, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist (IC50:0.38 and 0.72 nM for the human and the rat Y1 receptor).
Targets(IC50)	Neuropeptide Y Receptor
In vivo	BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding response mediated by 1 μg NPY. BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting [1]. BIBO3304 TFA (0.5?μM; p.o.) significantly increases serum insulin levels [2].

Solubility Information

Solubility	DMSO: 150 mg/mL (233.04 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 10 mg/mL (15.54 mM),Suspension. 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.13 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5536 mL	7.7681 mL	15.5362 mL
5 mM	0.3107 mL	1.5536 mL	3.1072 mL
10 mM	0.1554 mL	0.7768 mL	1.5536 mL
50 mM	0.0311 mL	0.1554 mL	0.3107 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wieland HA, et al. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol. 1998 Oct;125(3):549-55.
Loh K, et al. Inhibition of Y1 receptor signaling improves islet transplant outcome. Nat Commun. 2017 Sep 8;8(1): 490.